SPX4,309.12+11.98 0.28%
DIA341.80+2.43 0.72%
IXIC13,119.71-8.34 -0.06%

BRIEF-Turning Point Therapeutics Provides Regulatory Update For Repotrectinib For The Treatment Of Ros1+ Advanced Nsclc

BRIEF-Turning Point Therapeutics Provides Regulatory Update For Repotrectinib For The Treatment Of Ros1+ Advanced Nsclc

Reuters · 07/27/2022 18:16
BRIEF-Turning Point Therapeutics Provides Regulatory Update For Repotrectinib For The Treatment Of Ros1+ Advanced Nsclc

- Turning Point Therapeutics Inc TPTX:

  • TURNING POINT THERAPEUTICS PROVIDES REGULATORY UPDATE FOR REPOTRECTINIB FOR THE TREATMENT OF ROS1+ ADVANCED NSCLC

Source text for Eikon: ID:

Further company coverage: TPTX


((Reuters.Briefs@thomsonreuters.com;))